203 related articles for article (PubMed ID: 28085163)
1. PSMA-targeted contrast agents for intraoperative imaging of prostate cancer.
Bao K; Lee JH; Kang H; Park GK; El Fakhri G; Choi HS
Chem Commun (Camb); 2017 Feb; 53(10):1611-1614. PubMed ID: 28085163
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.
Pu F; Salarian M; Xue S; Qiao J; Feng J; Tan S; Patel A; Li X; Mamouni K; Hekmatyar K; Zou J; Wu D; Yang JJ
Nanoscale; 2016 Jul; 8(25):12668-82. PubMed ID: 26961235
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Targeted X-Ray Fluorescence Imaging via Gold Nanoparticles Functionalized With Prostate-Specific Membrane Antigen (PSMA).
Hara D; Tao W; Totiger TM; Pourmand A; Dogan N; Ford JC; Shi J; Pollack A
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):220-232. PubMed ID: 33964351
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
Wang Y; De Leon AC; Perera R; Abenojar E; Gopalakrishnan R; Basilion JP; Wang X; Exner AA
Sci Rep; 2021 Feb; 11(1):4726. PubMed ID: 33633232
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.
Lütje S; Heskamp S; Franssen GM; Frielink C; Kip A; Hekman M; Fracasso G; Colombatti M; Herrmann K; Boerman OC; Gotthardt M; Rijpkema M
Theranostics; 2019; 9(10):2924-2938. PubMed ID: 31244933
[No Abstract] [Full Text] [Related]
6. Fluorescence Detection of Prostate Cancer by an Activatable Fluorescence Probe for PSMA Carboxypeptidase Activity.
Kawatani M; Yamamoto K; Yamada D; Kamiya M; Miyakawa J; Miyama Y; Kojima R; Morikawa T; Kume H; Urano Y
J Am Chem Soc; 2019 Jul; 141(26):10409-10416. PubMed ID: 31244179
[TBL] [Abstract][Full Text] [Related]
7. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and preclinical evaluation of an Al
Huang Y; Li H; Ye S; Tang G; Liang Y; Hu K
Eur J Med Chem; 2021 Oct; 221():113502. PubMed ID: 33965863
[TBL] [Abstract][Full Text] [Related]
9. Imaging of Prostate-Specific Membrane Antigen Using [
Rowe SP; Gorin MA; Pomper MG
PET Clin; 2017 Jul; 12(3):289-296. PubMed ID: 28576167
[TBL] [Abstract][Full Text] [Related]
10. Application of an inhibitor-based probe to reveal the distribution of membrane PSMA in dSTORM imaging.
Jing Y; Cai M; Zhou L; Jiang J; Gao J; Wang H
Chem Commun (Camb); 2020 Nov; 56(86):13241-13244. PubMed ID: 33030161
[TBL] [Abstract][Full Text] [Related]
11. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.
Tse BW; Cowin GJ; Soekmadji C; Jovanovic L; Vasireddy RS; Ling MT; Khatri A; Liu T; Thierry B; Russell PJ
Nanomedicine (Lond); 2015 Feb; 10(3):375-86. PubMed ID: 25407827
[TBL] [Abstract][Full Text] [Related]
12. Development of targeted near-infrared imaging agents for prostate cancer.
Wang X; Huang SS; Heston WD; Guo H; Wang BC; Basilion JP
Mol Cancer Ther; 2014 Nov; 13(11):2595-606. PubMed ID: 25239933
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.
Mazzocco C; Fracasso G; Germain-Genevois C; Dugot-Senant N; Figini M; Colombatti M; Grenier N; Couillaud F
Sci Rep; 2016 Mar; 6():23314. PubMed ID: 26996325
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific membrane antigen-targeted photoacoustic imaging of prostate cancer in vivo.
Zhang HK; Chen Y; Kang J; Lisok A; Minn I; Pomper MG; Boctor EM
J Biophotonics; 2018 Sep; 11(9):e201800021. PubMed ID: 29653029
[TBL] [Abstract][Full Text] [Related]
15. A Fluorescent, [
Guo H; Kommidi H; Vedvyas Y; McCloskey JE; Zhang W; Chen N; Nurili F; Wu AP; Sayman HB; Akin O; Rodriguez EA; Aras O; Jin MM; Ting R
ACS Chem Biol; 2019 Jul; 14(7):1449-1459. PubMed ID: 31120734
[TBL] [Abstract][Full Text] [Related]
16. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.
Dannoon S; Ganguly T; Cahaya H; Geruntho JJ; Galliher MS; Beyer SK; Choy CJ; Hopkins MR; Regan M; Blecha JE; Skultetyova L; Drake CR; Jivan S; Barinka C; Jones EF; Berkman CE; VanBrocklin HF
J Med Chem; 2016 Jun; 59(12):5684-94. PubMed ID: 27228467
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer.
Kularatne SA; Thomas M; Myers CH; Gagare P; Kanduluru AK; Crian CJ; Cichocki BN
Clin Cancer Res; 2019 Jan; 25(1):177-187. PubMed ID: 30201762
[TBL] [Abstract][Full Text] [Related]
18. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
19. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer.
Maurer T; Schwamborn K; Schottelius M; Wester HJ; Schwaiger M; Gschwend JE; Eiber M
Clin Genitourin Cancer; 2016 Oct; 14(5):e549-e552. PubMed ID: 27318956
[No Abstract] [Full Text] [Related]
20. Design and synthesis of a novel BODIPY-labeled PSMA inhibitor.
Son SH; Kwon H; Ahn HH; Nam H; Kim K; Nam S; Choi D; Ha H; Minn I; Byun Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126894. PubMed ID: 31874825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
